Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Valuation and Earnings
This table compares Achieve Life Sciences and Aclaris Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achieve Life Sciences | N/A | N/A | -$54.65 million | ($1.12) | -4.39 |
| Aclaris Therapeutics | $7.83 million | 78.84 | -$64.92 million | ($0.56) | -7.89 |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Achieve Life Sciences and Aclaris Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achieve Life Sciences | 1 | 0 | 3 | 2 | 3.00 |
| Aclaris Therapeutics | 1 | 0 | 4 | 3 | 3.13 |
Achieve Life Sciences currently has a consensus price target of $14.67, suggesting a potential upside of 198.41%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 160.18%. Given Achieve Life Sciences’ higher probable upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than Aclaris Therapeutics.
Profitability
This table compares Achieve Life Sciences and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Achieve Life Sciences | N/A | -193.49% | -111.88% |
| Aclaris Therapeutics | -832.58% | -55.89% | -38.49% |
Insider and Institutional Ownership
33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Achieve Life Sciences has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
Summary
Aclaris Therapeutics beats Achieve Life Sciences on 9 of the 14 factors compared between the two stocks.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
